Viracta Therapeutics Analysis
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Viracta Therapeutics is overvalued with Real Value of 0.0286 and Hype Value of 0.03. The main objective of Viracta Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Viracta Therapeutics is worth, separate from its market price. There are two main types of Viracta Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Viracta Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Viracta |
Viracta Pink Sheet Analysis Notes
About 40.0% of the company outstanding shares are owned by institutional investors. The book value of Viracta Therapeutics was at this time reported as 0.33. The company recorded a loss per share of 1.1. Viracta Therapeutics last dividend was issued on the 3rd of September 2020. The entity had 285:1000 split on the 25th of February 2021. Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.The quote for Viracta Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Mark Rothera at 858 400 8470 or visit https://www.viracta.com.Viracta Therapeutics Investment Alerts
| Viracta Therapeutics is not yet fully synchronised with the market data | |
| Viracta Therapeutics generated a negative expected return over the last 90 days | |
| Viracta Therapeutics has high historical volatility and very poor performance | |
| Viracta Therapeutics has some characteristics of a very speculative penny stock | |
| Viracta Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.06 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Viracta Therapeutics Upcoming and Recent Events
Earnings reports are used by Viracta Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Viracta Therapeutics Thematic Classifications
In addition to having Viracta Therapeutics pink sheet in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Viracta Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.09 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Viracta Therapeutics's market, we take the total number of its shares issued and multiply it by Viracta Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Viracta Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viracta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viracta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viracta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viracta Therapeutics Outstanding Bonds
Viracta Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viracta Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viracta bonds can be classified according to their maturity, which is the date when Viracta Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Virgin Media Communications Corp BondUS92769VAJ89 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Viper Energy Partners Corp BondUS92763MAA36 | View | |
| Virgin Media 55 Corp BondUS92769XAP06 | View | |
| Virgin Media Investment Corp BondUS92769XAR61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Viracta Therapeutics Predictive Daily Indicators
Viracta Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Viracta Therapeutics pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Viracta Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Viracta Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Viracta shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Viracta Therapeutics. By using and applying Viracta Pink Sheet analysis, traders can create a robust methodology for identifying Viracta entry and exit points for their positions.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Viracta Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |